Program
MRNA-1283
A development code. Also written as “mRNA-1283”, “mRNA-1283.251 Variant-containing Formulation” and “mRNA-1283.222”.
Its studies are mostly in COVID-19 · Coronavirus Infections, led by Moderna.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Moderna | 73 open or running | phase 4since Jul 21, 2025 | Mar 22, 2021 | Dec 11, 2026phase 4 · NCT07863635 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 22, 2021First study: phase 1 study in Coronavirus InfectionsFirst studyNCT04813796 · 104 enrolled · United States
- Nov 24, 2021Phase 2 study in Coronavirus InfectionsNCT05137236 · 540 enrolled · United States
- Apr 13, 2023Phase 3 study in COVID-19NCT05815498 · 13,553 enrolled · United States, Canada, Japan and more
- Jul 21, 2025Phase 4 study in COVID-19NCT07089706 · 832 enrolled · United States
- Nov 25, 2025Phase 4 study in Coronavirus InfectionsNCT07266558 · 30,000 enrolled · United States
- Sep 2, 2026Phase 2 study in Coronavirus InfectionsNCT07808697 · 300 planned · United States, Argentina, Dominican Republic and more
- Oct 2, 2026Phase 4 study in Coronavirus InfectionsNCT07863635 · 600 planned · United States
Ahead
- Dec 11, 2026Primary completion: phase 4 study in Coronavirus InfectionsNCT07863635
- Jun 16, 2027Primary completion: phase 4 study in Coronavirus InfectionsNCT07266558
- Aug 30, 2029Primary completion: phase 2 study in Coronavirus InfectionsNCT07808697
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07863635Coronavirus Infections · United States | 4 | Recruiting | Dec 11, 2026 | 600 |
| NCT07808697Coronavirus Infections · United States, Argentina, Dominican Republic and more | 2 | Recruiting | Aug 30, 2029 | 300 |
| NCT07266558Coronavirus Infections · United States | 4 | Active, not recruiting | Jun 16, 2027 | 30,000 |
| NCT07089706COVID-19 · United States | 4 | Completed | Jun 16, 2026 | 832 |
| NCT05815498COVID-19 · United States, Canada, Japan and more | 3 | Completed | Apr 12, 2025 | 13,553 |
| NCT05137236Coronavirus Infections · United States | 2 | Completed | Mar 23, 2023 | 540 |
| NCT04813796Coronavirus Infections · United States | 1 | Completed | Jul 25, 2023 | 104 |
How it is read
Names in the registry
- “mRNA-1283”, 5 entries
- “mRNA-1283.251 Variant-containing Formulation”, 1 entry
- “mRNA-1283.222”, 1 entry
- “mRNA-1283.815”, 1 entry
- “mRNA-1283.211”, 1 entry
Codes read as this program: MRNA1283.
Conditions, from the studies’ own filings
- COVID-19, 6 studies
- Coronavirus Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.